CYH33|T38978|TargetMol

價格	￥10600
包裝	25mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2025-05-20

QQ交談微信洽談

產品詳情

中文名稱:CYH33	英文名稱:CYH33
CAS:1494684-28-4	品牌: TargetMol
產地: 美國	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
產品類別: 抑制劑
貨號: T38978

Product Introduction

Bioactivity

名稱	CYH33
描述	CYH33, an orally active and highly selective PI3Kα inhibitor, demonstrates specificity with IC50 values of 5.9 nM for the α isoform, 598 nM for β, 78.7 nM for δ, and 225 nM for γ. It effectively inhibits Akt and ERK phosphorylation and induces substantial G1 phase arrest in breast cancer and non-small cell lung cancer (NSCLC) cells, showcasing potent activity against solid tumors.
體外活性	CYH33 inhibits cell proliferation with IC 50 s below 1?μM in 56% (18/32) of the breast cancer cell lines[2]. CYH33 (0.012-1 μM; for 24 hours) significantly arrests T47D and MCF7 cells in G1 phase in a concentration-dependent manner[2]. CYH33 (4-1000 nM; 1 hour) concurrently inhibits phosphorylation of ERK and Akt in both T47D and MCF7 cells[2]. CYH33 (0.11-1 μM; 24 hours) fails to induce apoptosis in MCF7 and MDA-MB-231?cells[2]. Cell Cycle Analysis[2]Cell Line: Sensitive T47D, MCF7 and resistant MDA-MB-231 cells Concentration: 0.012, 0.037, 0.11, 0.33, 1 μM Incubation Time: For 24 hours Result: Arrested T47D and MCF7 cells in G1 phase in a concentration-dependent manner, accompanied with concomitant reduced cell population in S phase. Had little effect on cell cycle distribution in resistant MDA-MB-231?cells. Western Blot Analysis[2]Cell Line: Sensitive T47D, MCF7 and resistant MDA-MB-231 cells Concentration: 4, 12, 37, 111, 333, 1000 nM Incubation Time: 1 hour Result: Concurrently inhibited phosphorylation of ERK and Akt in both T47D and MCF7 cells, whereas it had little effect on phosphorylated ERK (pERK) in MDA-MB-231?cells up to 1?μM.
體內活性	CYH33 (2-20 mg/kg; oral; once a day for 21 days) potently restrains tumor growth in mice bearing human breast cancer cell xenografts[2]. Single administration of CYH33 (20?mg/kg; oral) significantly down-regulates the level of phosphorylated Akt in tumor tissues, demonstrating the suppression of PI3K signaling in nude mice[2]. CYH33 (10?mg/kg; oral; once a day for 18-d or 20-d respectively) delays the restoration of blood glucose and area under the curve (AUC) of blood glucose increased upon CYH33 treatment in T47D xenografts and R26-Pik3ca H1047R ;MMTV-Cre mice[2]. Animal Model: SCID mice aged 4-6 weeks bearing human breast cancer T47D xenografts[2]Dosage: 2, 5, 10, 20 mg/kg Administration: Oral; once a day for 21 days Result: Displayed marginal inhibitory effect on the tumor growth at lower doses (2 and 5?mg/kg) and significantly attenuated tumor growth at the dose of 10 or 20?mg/kg, yielding T/C values of 58.36% and 49.42% respectively.
存儲條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
關鍵字	CYH-33 \| CYH 33 \| CYH33

關鍵字： CYH33|TargetMol

公司簡介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領域科學家的研究提供專業(yè)的產品和服務。TargetMol?品牌的客戶群分布于40多個國家和地區(qū)，已發(fā)展成為全球知名的化合物庫和小分子化合物研究供應商。 TargetMol?可提供160多種滿足不同需求的化合物庫，以及多種類型的生化試劑產品，包括12000多種抑制劑、16000多種天然產物和各類多肽、抗體、生命科學試劑盒等，此外，我們還建設有CADD（計算機輔助藥物設計）研究中心、藥理實驗室、藥化合成平臺三大技術中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質的產品和服務、快速高效的全球供應鏈和專業(yè)的技術支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結果。

成立日期	2013-04-18 （13年）	注冊資本	589.8595萬人民幣
員工人數(shù)	100-500人	年營業(yè)額	￥ 1億以上
主營行業(yè)	中間體,天然產物,生物化工,化學試劑,生物技術服務	經(jīng)營模式	貿易,工廠,試劑,定制,服務

TargetMol中國（陶術生物）

VIP 2年

公司成立：13年
注冊資本：589.8595萬人民幣
企業(yè)類型：有限責任公司(自然人投資或控股)
主營產品：抑制劑&激動劑，天然產物，重組蛋白，化合物庫，技術服務
公司地址：上海市靜安區(qū)江場三路238號8樓

進入店鋪

詢盤

店內推薦

CLEC4A, Mouse, 重組蛋白 (hFc)|TMPK-00127|TargetMol

￥2660

化合物 hDDAH-1-IN-1|T11552|TargetMol

￥10600

化合物 Glutathione sulfinanilide|T68833|TargetMol